Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy"

Cancer Biology and Therapy

Volumn 8, Issue 1, 2009, Pages 13-17

  Gupta, Seema ^a   Singh, P K ^a   Bisht, S S ^a   Bhatt, M L B ^a   Pant, M C ^a   Gupta, R ^a   Gupta, D ^a   Negi, M P S ^b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Anemia; Cervix cancer; Epoetin alfa; Hematocrit; Hemoglobin; Recombinant human erythropoietin; Transfusion quality of life; Treatment

Indexed keywords

CISPLATIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLADDER DISEASE; BLOOD TRANSFUSION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOEMBOLISM; TREATMENT DURATION; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 66149088472     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.1.7089     Document Type: Article

References (42)

1. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692 (Pubitemid 20231525)
2. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21:3-8. (Pubitemid 24172363)
3. Nowrousian MR, Kasper C, Oberhoff C, Essers U, Voigtmann R, Gallasch, Quarder O. Pathophysiology of cancer-related anemia. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker, Inc 1996; 13-34.
4. Marchal L, Rangeard and Brunaud C. Anemia impact on treatments of cervical carcinomas. Cancer Radiother 2005; 9:87-95. (Pubitemid 40500381)
5. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic: quantitative review. Cancer 2001; 91:2214-2221 (Pubitemid 32552805)
6. Crawford J, Cella D, Charles S. Cleeland , Cremieux PY, Demetri GD, Sarokhan JB , Slavin BM, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:888-895
7. Goodnough LT. Risks of blood transfusion. Anemia and blood management in critical care. Critical Care Medicine 2003; 31:678-686
8. David H. Henry Symptom Management and Supportive Care The Evolving Role of Epoetin Alfa in Cancer Therapy. The Oncologist 2004; 9:97-107.
9. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003; 56:778-787 (Pubitemid 36677372)
10. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005; 63:25-36. (Pubitemid 41583539)
11. Dunst J. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing? Strahlenther Onkol 2004; 180:671-681
12. Kapp KS, Poschauko J, Geyer E, Berghold A, Oechs AC, Petru E, Lahousen M, Kapp DS. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54:58-66.
13. Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist 2004; 9:97-107. (Pubitemid 38134018)
14. Cheer SM, Wagstaff AJ. Epoetin Beta: A Review of its Clinical Use in the Treatment of Anaemia in Patients with Cancer. Adis Drug Evaluation Drugs 2004; 64:323-346 (Pubitemid 38292181)
15. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB. Dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001; 84:17-23. (Pubitemid 32453431)
16. Egrie JC, Browne JK. Development and characterization of darbepoetin alfa. Oncology 2002; 16:13-22.
17. Reed N, Morere JF. Optimizing Anaemia Management with Epoetin Beta. Oncology 2004; 67:12-16 (Pubitemid 39370541)
18. Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F. Epoetin Alfa Therapy Increases Hemoglobin Levels and Improves Quality of Life in Patients With Cancer-Related Anemia Who Are Not Receiving Chemotherapy and Patients With Anemia Who Are Receiving Chemotherapy. J Clin Oncol 2001; 19:4126-4134
19. Littlewood TJ, Bajetta E, Nortier WR, Vercammen E, Rapoport B. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol 2001; 19:2865-2874 (Pubitemid 32538196)
20. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D. Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. J Clin Oncol 2002; 20:2486-2494 (Pubitemid 34525734)
21. Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001; 28:54-59 (Pubitemid 32522239)
22. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004; 116:11-26. (Pubitemid 38429897)
23. Nowrousian MR. Pathophysiology of cancer-related anemia. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology. Wien-New York: Springer 2002.
24. Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma Strahlenther Onkol 2003; 179:8-15.
25. Odrazka K, Petera J, Kohlova T, Dolezel M, Vaculikova M, Zouhar M, Malek V, Hobza V, Latr I, Nemecek S, Sercl M, Ryska P, Blaha M, Cermakova E. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma. Strahlenther Onkol 2003; 179:615-619 (Pubitemid 37101645)
26. Overgaard J. The influence of hemoglobin concentration on the response to radiotherapy. Scand. J Clin Lab Invest 1988; 48:49-53. (Pubitemid 18274675)
27. Overgaard J, Hansen HS, Jorgensen K, Hjelm M. Primary radiotherapy of larynx and pharynx carcinoma-an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986; 12:515-521 (Pubitemid 16081611)
28. Pederson D, Sogaard H, Overgaard J, Bentzen SM. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol 1995; 34:787-795
29. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42:1069-1075 (Pubitemid 29004150)
30. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260 (Pubitemid 37324251)
31. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennet CL, Langensiepen S, Hyde C, Enger A. Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 studies including 9353 Patients. JNCI 2006; 98:708-714
32. Lee J, Miller CB, Rarick MU, Regan DH, Browman GP, Rizzo D, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Stephanie J. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology, Blood 2002;100:2303-2320
33. Thomas G. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12 g/dl with Erythropoietin vs above 10 g/dl without Erythropoietin in anaemic patients receiving concurrent radiation and cisplatin for carcinoma cervix. Gynecol oncol 2008; 108:317-325
34. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97:489-498 (Pubitemid 40590430)
35. Throuvalas N, Antonadou D, Lavey R, Boufi M, Malamos N. Final results of a randomized phase II study evaluating the role of erythropoietin during radiochemotherapy for pelvic tumors. Int J Radiat Oncol Biol Phys 2004; 60:300.
36. Villar A, Cabezon MA, de Serdio JL, Fuentes C, Espiñeira M, Perez MD, Gil J, Artazkoz JJ, Borque C, Suñer M, Saavedra JA. Hyperfractionated chemoradiation with carbogen breathing, with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:47-53. (Pubitemid 32318561)
37. Fred R. Rosen, Daniel J. Haraf, Merrill S. Kies, Kerstin Stenson, Louis Portugal, Marcy A. List, Bruce E. Brockstein, Bharat B. Mittal, Alfred W. Rademaker, Mary Ellyn Witt, Harold Pelzer, Ralph R. Weichselbaum and Everett E. Vokes. Multicenter Randomized Phase II Study of Paclitaxel (1-Hour Infusion), Fluorouracil, Hydroxyurea, and Concomitant Twice Daily Radiation with or without Erythropoietin for Advanced Head and Neck Cancer Clinical Cancer Research 2003; 9:1689-1697
38. Lavey RS, Liu PY, Greer BE, Robinson WR, 3rd, Chang PC, Wynn RB, Conrad ME, Jiang C, Markman M, Alberts DS. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol 2004; 95:145-151
39. Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R, Ressler P, Kentenich H, Kohls A, Lichtenegger W. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study(abstract # 447PD). Ann Oncol 2004; 15.
40. Strauss H, Haensgen G, Dunst J, Hayward C, Koelbl H. Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy. J Clin Onco 2005; 23:5121.
41. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2006; Issue 3. Art. No.: CD003407. DOI: 10.1002/14651858.CD003407.
42. nd ed.) New Jersey: Lawrence Erlbaum 1988.